New findings provide more complete picture of kidney cancer

Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments.

In a study published in Cancer Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, Ph.D., researchers provide a more complete understanding of the biology of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive type of with no effective treatment, which lays the foundation for the development of effective .

Despite obvious morphological, genetic, and clinical differences, hereditary PRCC2 is thought to share similar pathway deregulation due to genetic mutation with its counterpart, clear cell (CCRCC), a subtype that accounts for 75% of all kidney cancers and that, unlike PRCC2, responds favorably to drugs targeting (VEGF), a signal protein produced by cells that stimulate .

The study, which included international collaboration with researchers from the National Cancer Centre Singapore, Génétique Oncologique EPFE-INSERM U753 and Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre and Institut de Cancérologie Gustave Roussy, Michigan State University, Northwestern Memorial Hospital, Cleveland Clinic, Singapore General Hospital, and The Wistar Institute, identified deregulation of the KEAP1-NRF2 signaling pathway as a factor that distinguishes PRCC2 from CCRCC, but links both hereditary and sporadic PRCC2.

In another study published in Cancer Research, led by Yan Ding, Ph.D., and Bin Tean Teh, Ph.D. and carried out in collaboration with the National Cancer Centre Singapore, researchers integrated gene expression profiling and RNAi screening data to identify genes involved in CCRCC development and progression.

In recent years, several molecularly targeted therapies such as sunitinib, sorafenib, and pazopanib, which target the receptor tyrosine kinases of VEGF have been approved for CCRCC. Although these therapies significantly extend overall survival, nearly all patients with advanced CCRCC eventually succumb to the disease.

Gene set enrichment analysis indicated that cell-cycle-related genes, in particular PLK1, were associated with disease aggressiveness. Further, the association of PLK1 in both disease aggression and in vitro growth prompted researchers to examine the effects of a small-molecule inhibitor in CCRCC cell lines. Their findings highlight PLK1 as a promising potential therapeutic target for CCRCC.

Provided by Van Andel Research Institute

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

New findings may help patients with deadly kidney cancer

Feb 18, 2010

Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of ...

Researchers find genetic secrets to common kidney cancer

May 18, 2010

By examining expression of every human gene in clear cell renal cell carcinoma (ccRCC) compared to normal kidney cells, researchers at Mayo Clinic's campus in Florida have discovered gene signatures they say explain much ...

Researchers find gene they believe is key to kidney cancer

May 20, 2010

Researchers at Mayo Clinic's campus in Florida have discovered a key gene that, when turned off, promotes the development of common kidney cancer. Their findings suggest that a combination of agents now being tested in other ...

Recommended for you

Aspirin may lower the risk for aggressive prostate cancer

4 hours ago

Use of aspirin and/or other non-steroidal anti-inflammatory drugs (NSAIDs) was associated with a reduced risk for aggressive prostate cancer in men who had elevated prostate specific antigen (PSA) and a negative biopsy prior ...

User comments